The Centers for Medicare & Medicaid Services (CMS) and the Trump administration are ending the Medicare Part D drug subsidy program [1].
This policy change matters because it removes financial assistance that helped keep prescription drug costs lower for beneficiaries. Without this support, premiums for Medicare Part D plans could rise in 2027 [2].
Federal officials said a desire to reduce government spending on drug price assistance was the primary reason for the move [1]. The administration also said cost-shifting to insurers was a factor in the decision [1]. This shift in policy may affect millions of seniors across the U.S. [3].
Beneficiaries must navigate the upcoming open enrollment period to manage their costs. The window for selecting 2027 plans closes on Dec. 7, 2026 [1]. Because the subsidy ends for 2027 premiums, patients may see different pricing structures when they review their options this winter [1].
There has been internal disagreement regarding the origin of the subsidy's structure. While the current administration is executing the end of the program, some officials said the need for the change was due to previous policies that bailed out insurers with subsidies [3].
CMS has not yet released specific figures on the exact premium increases patients should expect. However, the removal of the subsidy generally leads to higher monthly costs for the end user [2]. Patients are encouraged to compare plans during the enrollment window to find the most affordable coverage for their specific medication needs.
“Premiums for Medicare Part D could rise in 2027 because the subsidy ends”
The termination of this subsidy represents a pivot toward reducing federal expenditures in healthcare, shifting the financial burden from the government to the individual beneficiary and private insurers. This creates a critical deadline for seniors who must now actively shop for new plans to avoid unexpected price hikes in their monthly healthcare budgets.
